Ironwood Pharmaceuticals (NASDAQ:IRWD) Upgraded to Strong-Buy at Craig Hallum

Ironwood Pharmaceuticals (NASDAQ:IRWD) was upgraded by investment analysts at Craig Hallum from a “hold” rating to a “strong-buy” rating in a report issued on Monday,Zacks.com reports.

Other research analysts have also recently issued research reports about the stock. Citigroup raised shares of Ironwood Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Monday. Zacks Research raised Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 1st. Citizens Jmp raised Ironwood Pharmaceuticals from a “market perform” rating to a “market outperform” rating and set a $8.00 target price on the stock in a report on Monday. Weiss Ratings reissued a “sell (d)” rating on shares of Ironwood Pharmaceuticals in a report on Monday, December 29th. Finally, Wells Fargo & Company upped their price objective on Ironwood Pharmaceuticals from $3.00 to $5.00 and gave the stock an “equal weight” rating in a research report on Monday. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $6.12.

Ironwood Pharmaceuticals Stock Up 7.5%

Shares of Ironwood Pharmaceuticals stock opened at $4.59 on Monday. The company has a 50 day moving average price of $3.12 and a 200 day moving average price of $1.82. The firm has a market capitalization of $746.70 million, a P/E ratio of 28.69 and a beta of 0.18. Ironwood Pharmaceuticals has a 52 week low of $0.53 and a 52 week high of $5.78.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings data on Monday, November 10th. The biotechnology company reported $0.24 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.15. The firm had revenue of $122.06 million for the quarter, compared to analyst estimates of $74.22 million. Ironwood Pharmaceuticals had a net margin of 8.70% and a negative return on equity of 15.17%. As a group, research analysts anticipate that Ironwood Pharmaceuticals will post 0.1 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. OVERSEA CHINESE BANKING Corp Ltd purchased a new stake in Ironwood Pharmaceuticals in the 2nd quarter worth $25,000. Integrated Wealth Concepts LLC increased its stake in shares of Ironwood Pharmaceuticals by 21.4% during the third quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 3,406 shares in the last quarter. R Squared Ltd raised its position in shares of Ironwood Pharmaceuticals by 286.5% during the 2nd quarter. R Squared Ltd now owns 38,765 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 28,735 shares during the last quarter. Focus Partners Advisor Solutions LLC lifted its stake in Ironwood Pharmaceuticals by 284.6% in the 2nd quarter. Focus Partners Advisor Solutions LLC now owns 39,743 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 29,409 shares in the last quarter. Finally, Captrust Financial Advisors purchased a new position in Ironwood Pharmaceuticals in the 2nd quarter valued at about $32,000.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.